Second-generation antipsychotic medications associated with high metabolic risk (quetiapine, olanzapine, and clozapine) were associated with increased risk of gestational diabetes; other antipsychotics were not.
Prenatal exposure to antipsychotic medications was not associated with increased risk of neurodevelopmental disorders in offspring.
The most recent publication from the National Pregnancy Registry focuses on overall risk of malformations associated with the class of antipsychotic medications.
The use of the newer “atypical” or second-generation antipsychotic agents is increasing. Atypical antipsychotics are now used to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and other anxiety [...]
